Related Experiment Video
Updated: Sep 20, 2025
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Active Treatment vs Expectant Management of Patent Ductus Arteriosus in Preterm Infants: A Meta-Analysis
Santosi Buvaneswarran1,2, Yi Ling Wong2, Shen Liang3
1Department of Neonatology, Khoo Teck Puat National University Children's Medical Institute, National University Hospital, National University Health System, Singapore.
Insights
Active treatment for patent ductus arteriosus (PDA) in preterm infants increased death or bronchopulmonary dysplasia (BPD) and mortality. Expectant management may offer better outcomes for hemodynamically significant PDA.
Area of Science:
- Neonatalogy
- Pediatric Cardiology
- Clinical Research
Background:
- Hemodynamically significant patent ductus arteriosus (PDA) is common in preterm infants.
- Evidence suggests expectant management may yield better outcomes than active treatment.
- Optimal management strategies for PDA in preterm infants require further investigation.
Purpose of the Study:
- To compare clinical outcomes of active treatment versus expectant management for hemodynamically significant PDA in preterm infants.
- To evaluate the impact of different PDA management strategies on mortality and morbidity.
Main Methods:
- A systematic search of PubMed, Embase, and Cochrane Library for randomized clinical trials (RCTs) published between January 2010 and July 2024.
- Included RCTs enrolled preterm infants (born before 33 weeks gestation) comparing active treatment and expectant management.
- Meta-analysis used a random-effects model to pool data from 10 RCTs involving 2035 infants.
Main Results:
- Active PDA treatment was associated with a higher incidence of death or moderate to severe bronchopulmonary dysplasia (BPD) (56.2% vs 50.8%).
- Mortality at 36 weeks was significantly higher in the active treatment group (14.3% vs 11.2%).
- No significant difference was observed in moderate to severe BPD or periventricular leukomalacia (PVL) rates between groups.
Conclusions:
- Active treatment of hemodynamically significant PDA in the first two weeks of life is linked to increased mortality and BPD.
- Expectant management appears to be associated with better outcomes compared to active treatment.
- Further research is warranted to refine clinical protocols for managing PDA in preterm neonates.
Importance:
Recent evidence suggests that expectant management of hemodynamically significant patent ductus arteriosus (PDA) may confer better outcomes.
Objective:
To assess clinical outcomes of active treatment vs expectant management of hemodynamically significant PDA in preterm infants.
Data Sources:
The PubMed (MEDLINE), Embase, and Cochrane Library databases were searched for randomized clinical trials (RCTs) published between January 1, 2010, and July 31, 2024.
Study Selection:
RCTs were included if they enrolled preterm infants born before 33 weeks of gestation and had 2 groups comparing active treatment with expectant management.
Data Extraction And Synthesis:
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed. Data were extracted by 2 independent reviewers. The Cochrane Risk of Bias tool was used to assess study quality. A random-effects model was used to estimate the pooled effects.
Main Outcomes And Measures:
The primary outcomes were a composite of death at 36 weeks' postmenstrual age or at discharge (whichever occurred later) or moderate to severe bronchopulmonary dysplasia (BPD), death at 36 weeks, and moderate to severe BPD. Secondary outcomes included intraventricular hemorrhage, periventricular leukomalacia (PVL), retinopathy of prematurity, and necrotizing enterocolitis.
Results:
This meta-analysis included 10 RCTs involving 2035 infants. There were 1018 infants in the active treatment group (510 female [50.1%]) and 1017 infants (551 male [54.2%]) in the expectant management group. The mean (SD) gestational age was 26.2 (1.7) weeks vs 26.3 (1.7) weeks, and the mean (SD) birth weight was 874.7 (222.1) g vs 897.7 (216.5) g, respectively. The incidence of the composite outcome (death at 36 weeks or at discharge or moderate to severe BPD) was higher in the active treatment group vs the expectant management group (516 of 918 [56.2%] vs 465 of 915 [50.8%]; relative risk [RR], 1.10 [95% CI, 1.01-1.19]; P = .02). Deaths at 36 weeks were higher in the active treatment group (139 of 974 [14.3%] vs 109 of 969 [11.2%]; RR, 1.27 [95% CI, 1.01-1.61]; P = .04). There were nonsignificant increases in moderate to severe BPD (372 of 785 [47.4%] vs 349 of 806 [43.3%]; RR, 1.08 [95% CI, 0.95-1.23]; P = .25) and PVL (52 of 913 [5.7%] vs 32 of 908 [3.5%]; RR, 1.50 [95% CI, 0.98-2.30]; P = .06) in the active treatment group vs the expectant management group.
Conclusions And Relevance:
This meta-analysis found that active treatment of hemodynamically significant PDA during the first 2 weeks of life was associated with a significantly higher incidence of death or moderate to severe BPD and with increased mortality compared with an expectant management approach. Further research is needed for revision of protocols for PDA management.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:25Aortic Regurgitation III: Medical Management